Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LDL Cholesterol Clear all
Completed Not applicable Interventional

Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study

NCT02086539
View directory record Official record
Conditions
Diabetes
Interventions
Large Envelope, Priority Mail, Amazon
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00280995
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Almonds on Cardiovascular Risk Factors

NCT01101230
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Almonds
Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 4 Interventional

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691
View directory record Official record
Conditions
Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
181
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated May 2, 2007 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional

The Effects of Strawberries on Blood Cholesterol.

NCT03441620
View directory record Official record
Conditions
Hyper-LDL-cholesterolemia, Metabolic Syndrome
Interventions
strawberries, Control powder
Dietary Supplement · Other
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Las Vegas, Nevada • Oklahoma City, Oklahoma • Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

NCT01763918
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 20, 2026, 9:56 AM EDT
Recruiting Phase 4 Interventional

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

NCT06865885
View directory record Official record
Conditions
Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

NCT03051100
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654
View directory record Official record
Conditions
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients

NCT00569959
View directory record Official record
Conditions
Diabetes Mellitus, Normal Glucose Metabolism, Hyperlipidemia
Interventions
fasting 12+ hours, Non-fasting
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

NCT01879319
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab AMD, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stop Atherosclerosis in Native Diabetics Study

NCT00147251
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
Interventions
FDA approved drugs to treat blood pressure and cholesterol
Drug
Lead sponsor
Cynthia West
Other
Eligibility
40 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

NCT01624142
View directory record Official record
Conditions
Severe Familial Hypercholesterolemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism

NCT00860509
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Low Phytosterol and High Phytosterol Diets
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers

NCT03118583
View directory record Official record
Conditions
Healthy Volunteers
Interventions
300 mg/day of dietary supplement containing carrageenan
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
25 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 20, 2026, 9:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

NCT03705234
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
University of Oxford
Other
Eligibility
40 Years and older
Enrollment
16,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2049
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

NCT01858376
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Capros dietary supplement
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 20, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

NCT01763827
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 20, 2026, 9:56 AM EDT